Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Agomelatine versus sertraline for anxiety and depression in patients with psychogenic non-epileptic seizures
IRCT20230626058586N3Phase 2Completed
- Sponsor
- Shahid Beheshti University of Medical Sciences
- Start
- Feb 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in anxiety disorder and major depressive disorder (MDD) comparing Agomelatine with Sertraline (2 arms). Primary endpoints: Level of anxiety and Level of depression. Started Feb 2024; status: completed.
02
Drugs
agomelatinesertraline
03
Conditions
anxiety disordermajor depressive disorder (MDD)
Beyond the preview
Go deeper on IRCT20230626058586N3.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20230626058586N3.